Eli Lilly and Company (NYSE: LLY) announced that its targeted therapy Retevmo (selpercatinib) cut the risk of disease recurrence or death by 83 percent versus placebo in patients with…
Johnson & Johnson (NYSE: JNJ) has received FDA approval for a label expansion for TREMFYA (guselkumab), confirming it as the only IL‑23 inhibitor proven to…
May 28, 2026
Kailera Therapeutics, Inc. Follows a Validated Biological Path in the Lucrative Weight Loss Sector
Kailera Therapeutics, Inc. (NASDAQ: KLRA) recently completed a record-breaking initial public offering to fund its advanced metabolic pipeline. This historic market debut for Kailera Therapeutics…
Alife Health has received FDA clearance for its AI powered embryo assessment software, which is designed to help IVF clinics grade and prioritize embryos more…
BridgeBio Pharma (NASDAQ: BBIO) has received FDA acceptance and Priority Review for its investigational therapy BBP-418, which could become the first-ever approved treatment for limb-girdle…
Aptevo Therapeutics Inc. (NASDAQ: APVO) and Niowave Inc. are forming a 50/50 partnership to develop up to three radiopharmaceutical cancer drugs, giving both companies a…
Eli Lilly and Company (NYSE: LLY) is making a major push back into vaccines, signing deals worth up to 3.8 billion dollars to acquire three…
Virginia Tech researchers are advancing a noninvasive, sound‑based approach to breaking up kidney stones that could make treatment faster, more comfortable, and more widely accessible…
PharmAla Biotech’s (OTCQB: MDXXF) new licensing term sheet with Jupiter Neurosciences (NASDAQ: JUNS) gives Jupiter a differentiated MDMA‑based CNS asset while providing PharmAla with upfront…
Relay Therapeutics Inc. (NASDAQ: RLAY) is jumping after the company reported encouraging initial data from its Phase 2 ReInspire trial of zovegalisib (RLY‑2608) in patients with rare,…
Artivion, Inc. (NYSE: AORT) is paying about $135 million upfront to acquire Endospan Ltd., locking in the FDA‑approved NEXUS Aortic Arch System and significantly strengthening its aortic…
3D Systems Corp. (NYSE: DDD) finally has some momentum again, with Q1 2026 showing a clean return to growth after last year’s restructuring and divestitures….